Literature DB >> 26512351

Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma.

Ju Hyun Ahn1, Wan Hyeong Cho2, Jun Ah Lee1, Dong Ho Kim1, Ju-Hee Seo1, Jung Sub Lim1.   

Abstract

PURPOSE: Osteoporosis is currently receiving particular attention as a sequela in survivors of childhood osteosarcoma. The aim of this study was to evaluate bone mineral density (BMD) changes during methotrexate-based chemotherapy in children and adolescents with osteosarcoma.
METHODS: Nine patients with osteosarcoma were included in this retrospective study and compared with eight healthy controls. BMD of the lumbar spine and unaffected femur neck of patients was serially measured by dual-energy x-ray absorptiometry (DXA) before and just after chemotherapy and compared with controls.
RESULTS: Four patients (44%) showed decreased lumbar spine BMD and seven patients (78%) showed decreased femur neck BMD, while all controls showed increased lumbar and femur BMD (P=0.024 and P=0.023). The femur neck BMD z-scores decreased from -0.49±1.14 to -1.63±1.50 (P=0.032). At the end of therapy, five patients (56%) showed femur neck BMD z-scores below -2.0.
CONCLUSION: The bone metabolism is disturbed during therapy in children with osteosarcoma, resulting in a reduced BMD with respect to healthy controls. Since a reduced BMD predisposes to osteoporosis, specific attention and therapeutic interventions should be considered.

Entities:  

Keywords:  Bone density; Korea; Osteoporosis; Osteosarcoma

Year:  2015        PMID: 26512351      PMCID: PMC4623343          DOI: 10.6065/apem.2015.20.3.150

Source DB:  PubMed          Journal:  Ann Pediatr Endocrinol Metab        ISSN: 2287-1012


  25 in total

Review 1.  Bone loss and fracture risk associated with cancer therapy.

Authors:  Theresa A Guise
Journal:  Oncologist       Date:  2006 Nov-Dec

Review 2.  Osteoporosis due to cancer treatment: pathogenesis and management.

Authors:  J Pfeilschifter; I J Diel
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

Review 3.  Cisplatin and hypomagnesemia.

Authors:  H Lajer; G Daugaard
Journal:  Cancer Treat Rev       Date:  1999-02       Impact factor: 12.111

4.  Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.

Authors:  Fani Athanassiadou; Athanassios Tragiannidis; Israel Rousso; Georgios Katsos; Vassiliki Sidi; Dimitrios Koliouskas; Cristos Papastergiou; Ioannis Tsituridis
Journal:  Pediatr Hematol Oncol       Date:  2005-06       Impact factor: 1.969

5.  Altered mineral metabolism and bone mass in children during treatment for acute lymphoblastic leukemia.

Authors:  J M Halton; S A Atkinson; L Fraher; C Webber; G J Gill; S Dawson; R D Barr
Journal:  J Bone Miner Res       Date:  1996-11       Impact factor: 6.741

6.  Bone mineral density according to age, bone age, and pubertal stages in korean children and adolescents.

Authors:  Jung Sub Lim; Jin Soon Hwang; Jun Ah Lee; Dong Ho Kim; Kyung Duk Park; Gi Jeong Cheon; Choong Ho Shin; Sei Won Yang
Journal:  J Clin Densitom       Date:  2009-11-26       Impact factor: 2.617

7.  High-dose methotrexate in osteogenic sarcoma.

Authors:  N Jaffe; M P Link; D Cohen; D Traggis; E Frei; H Watts; G P Beardsley; H T Abelson
Journal:  Natl Cancer Inst Monogr       Date:  1981-04

8.  Osteosarcoma developed in the period of maximal growth rate have inferior prognosis.

Authors:  Jun Ah Lee; Min Suk Kim; Dong Ho Kim; Jung Sub Lim; Kyung Duk Park; Won Seok Song; Soo-Yong Lee; Dae-Geun Jeon
Journal:  J Pediatr Hematol Oncol       Date:  2008-06       Impact factor: 1.289

Review 9.  Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature.

Authors:  Karen Wasilewski-Masker; Sue C Kaste; Melissa M Hudson; Natia Esiashvili; Leonard A Mattano; Lillian R Meacham
Journal:  Pediatrics       Date:  2008-03       Impact factor: 7.124

10.  Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia.

Authors:  Inge M van der Sluis; Marry M van den Heuvel-Eibrink; Karel Hählen; Eric P Krenning; Sabine M P F de Muinck Keizer-Schrama
Journal:  J Pediatr       Date:  2002-08       Impact factor: 4.406

View more
  6 in total

Review 1.  The Role of Nutritional Status, Gastrointestinal Peptides, and Endocannabinoids in the Prognosis and Treatment of Children with Cancer.

Authors:  Magdalena Schab; Szymon Skoczen
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

2.  Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density.

Authors:  Se Won Lim; Ju Hyun Ahn; Aery Choi; Wan Hyeong Cho; Jun Ah Lee; Dong Ho Kim; Ju-Hee Seo; Jung Sub Lim
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-03-31

3.  Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo.

Authors:  Aurélie Moniot; Julien Braux; Camille Bour; Christine Guillaume; Fabien Lamret; Ingrid Allart-Simon; Sandra Audonnet; Sarah Renault; Francoise Rédini; Marie Laronze-Cochard; Janos Sapi; Sophie C Gangloff; Stéphane Gérard; Frédéric Velard
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

4.  Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma.

Authors:  Francesca Punzo; Chiara Tortora; Daniela Di Pinto; Iolanda Manzo; Giulia Bellini; Fiorina Casale; Francesca Rossi
Journal:  Oncotarget       Date:  2017-04-13

5.  A correlation analysis between tumor imaging changes and p-AKT and HSP70 expression in tumor cells after osteosarcoma chemotherapy.

Authors:  Feng Ji; Ran Lv; Ting Zhao
Journal:  Oncol Lett       Date:  2017-09-20       Impact factor: 2.967

6.  Can Denosumab be used in combination with Doxorubicin in Osteosarcoma?

Authors:  Francesca Punzo; Chiara Tortora; Maura Argenziano; Daniela Di Pinto; Elvira Pota; Martina Di Martino; Alessandra Di Paola; Francesca Rossi
Journal:  Oncotarget       Date:  2020-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.